Search Results 11-20 of 17322 for egfr
... (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma multiforme (GBM) expressing EGFR alterations ...
Furthermore, progression from a lesser stage to CKD stage 3B or higher (eGFR < 45 mL/min/1.73m2) has been associated with increased cardiovascular events and ...
A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) ...
TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell ...
Creatinine with estimated glomerular filtration rate (eGFR), serum. Mayo Clinic Laboratories. https://www.mayocliniclabs.com/test-catalog/overview/48216 ...
An Open-label Study Using ASP-1929 Photoimmunotherapy In Combination With Anti-PD1 Therapy In EGFR Expressing Advanced Solid Tumors. Print details. Share ...
Phase 2 will further evaluate the antitumor efficacy and safety in specified cohorts determined by EGFR/HER2 mutation subtypes and/or treatment history at the ...
Doctors check you for other serious conditions, including chronic infections, cancer, and heart and blood vessel disease, also called cardiovascular disease.
... EGFR mutated and cMET amplified advanced/metastatic non-small cell lung cancer,and have acquired resistance to prior EGFR tyrosine kinase inhibitors.
A transplant nephrologist at Mayo Clinic outlines suggested criteria for referring a patient for a potential kidney transplant.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!